Response strategies against meningitis epidemics after elimination of serogroup a meningococci, Niger

Emerging Infectious Diseases

Volumn 21, Issue 8, 2015, Pages 1322-1329

  Maïnassara, Halima Boubacar ^a,b,c   Paireau, Juliette ^a,b   Idi, Issa ^c   Pelat, Jean Paul Moulia ^c   Oukem Boyer, Odile Ouwe Missi ^c   Fontanet, Arnaud ^b,d   Mueller, Judith E ^b,e  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PASTEUR   (France)

^c Centre de Recherche Médicale et Sanitaire   (Niger)

^d Inst S et Developpement   (France)

^e EHESP SCHOOL OF PUBLIC HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCAL SEROGROUP A CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE SURVEILLANCE; DRUG EFFICACY; EPIDEMIC; HEALTH SURVEY; HUMAN; MENINGITIS; MORBIDITY; MULTIPLEX POLYMERASE CHAIN REACTION; NEISSERIA MENINGITIDIS; NIGER; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VACCINATION; DISEASE OUTBREAKS; MENINGITIS, MENINGOCOCCAL; PROCEDURES; STATISTICS AND NUMERICAL DATA;

DISEASE OUTBREAKS; EPIDEMICS; HUMANS; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP A; NIGER; POPULATION SURVEILLANCE;

EID: 84937460064     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2108.141361     Document Type: Article

References (24)

1. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007; 44:657-63. http://dx.doi.org/10.1086/511646
2. Delrieu I, Yaro S, Tamekloé TAS, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE. 2011;6:e19513. http://dx.doi.org/10.1371/journal.pone.0019513
3. Mueller JE, Yaro S, Njanpop-Lafourcade B, Drabo A, Idohou RS, Kroman SS, et al. Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage and immunity. J Infect Dis. 2011;204:1787-95. http://dx.doi.org/10.1093/infdis/jir623
4. MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FV, et al. Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis. 2014;20:394-9. http://dx.doi.org/10.3201/eid2003.131407
5. Collard JM, Issaka B, Zaneidou M, Hugonnet S, Nicolas P, Taha MK, et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis. 2013;13:576. http://dx.doi.org/ 10.1186/1471-2334-13-576
6. World Health Organization. Detecting meningococcal meningitis epidemics in highly-endemic African countries. WHO recommendation. Wkly Epidemiol Rec. 2000;75:306-9.
7. World Health Organization. Meningitis outbreak response in sub-Saharan Africa. WHO guideline [cited 2015 May 28]. http://www.who.int/csr/resources/publications/meningitis/ guidelines2014/en/
8. Gagneux SP, Hodgson A, Smith TA, Wirth T, Ehrhard I, Morelli G, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis. 2002; 185:618-26. http://dx.doi.org/10.1086/339010
9. Mueller JE, Borrow R, Gessner BD. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines. 2006;5:319-36. http://dx.doi.org/10.1586/14760584.5.3.319
10. Tall H, Hugonnet S, Donnen P, Dramaix-Wilmet M, Kambou L, Drabo F, et al. Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study. BMC Infect Dis. 2012;12:2. http://dx.doi.org/10.1186/ 1471-2334-12-2
11. Paireau J, Girond F, Collard JM, Maïnassara HB, Jusot JF. Analysing spatio-temporal clustering of meningococcal meningitis outbreaks in Niger reveals opportunities for improved disease control. PLoS Negl Trop Dis. 2012;6:e1577.
12. World Health Organization. Control of epidemics meningococcal disease. WHO practical guidelines. 2nd ed. WHO/EMC/BAC98.3. Geneva: The Organization; 1998.
13. World Health Organization. Recommended standards for surveillance of selected vaccine-preventable disease. Geneva: The Organization; 2003.
14. Chanteau S, Sidikou F, Djibo S, Moussa A, Mindadou H, Boisier P. Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt: indisputable benefits of multiplex PCR assay in Niger. Trans R Soc Trop Med Hyg. 2006;100:677-80. http://dx.doi.org/10.1016/j.trstmh.2005.09.006
15. Institut National de la Statistique-Niger. Annuaire statistique "Séries longues 1990-2006." Edition 2007 [cited 2013 Mar 25]. http://www.stat-nger.org/statistique/file/jms/CATALOGUE_ jms2010.pdf
16. Maïnassara HB, Sidikou F, Djibo S, Soussou AM, Issaka BB, Sidiki A, et al. Epidemiological patterns of bacterial meningitis in Niger from 2002 to 2010. Science Journal of Public Health. 2014; 2:58-63.
17. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2:114-8. http://dx.doi.org/10.1016/ S0140-6736(85)90224-7
18. Soriano-Gabarró M, Toé L, Tiendrebeogo SRM, Nelson CB, Dabal M, Djingarey MH, et al. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine. 2007;2S:A92-6. http://dx.doi.org/ 10.1016/j.vaccine.2007.04.048
19. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity serologic correlates of protection for evaluating the response to meningococcal vaccines. Clin Vaccine Immunol. 2010;17:840-7. http://dx.doi.org/10.1128/CVI.00529-09
20. Institut National de la Statistique-Niger 2013. Le Niger en chiffres 2013 [cited 2013 Mar 22]. http://www.stat-niger.org/statistique/file/ Affiches_Depliants/Nigerenchiffres2013-versi.pdf
21. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011;364:2293-304. http://dx.doi.org/10.1056/NEJMoa1003812
22. Kim SH, Pezzoli L, Yacouba H, Coulibaly T, Djingarey MH, Perea WA, et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS ONE. 2012;7:e29116. http://dx.doi.org/10.1371/journal.pone.0029116
23. Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383:40-7. http://dx.doi.org/10.1016/S0140-6736(13)61612-8
24. Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354-63. http://dx.doi.org/10.1093/cid/cis892